Evommune (EVMN) director sells 6,056 shares and receives option grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Evommune director David E. Cohen reported both stock sales and a new option grant. He sold a total of 6,056 shares of common stock in two open-market transactions at weighted average prices of $20.21 and $21.38, executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026.
On the same date, he received a grant of stock options covering 15,673 shares of common stock with an exercise price of $19.82 per share, expiring on June 1, 2036. These options vest at the earlier of the first anniversary of the grant date or Evommune’s next annual meeting of stockholders, as long as he continues to serve through that date.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 6,056 shares ($123,094)
Net Sell
3 txns
Insider
Cohen David E
Role
null
Sold
6,056 shs ($123K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) | 15,673 | $0.00 | -- |
| Sale | Common Stock | 5,456 | $20.21 | $110K |
| Sale | Common Stock | 600 | $21.38 | $13K |
Holdings After Transaction:
Stock Option (Right to buy) — 15,673 shares (Direct, null);
Common Stock — 18,209 shares (Direct, null)
Footnotes (1)
- The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
Total shares sold: 6,056 shares
Sale price (block 1): $20.21 per share
Sale price (block 2): $21.38 per share
+4 more
7 metrics
Total shares sold
6,056 shares
Open-market sales of Evommune common stock on June 2, 2026
Sale price (block 1)
$20.21 per share
Weighted average price for 5,456 shares sold
Sale price (block 2)
$21.38 per share
Weighted average price for 600 shares sold
Option grant size
15,673 shares
Stock option (right to buy) granted June 2, 2026
Option exercise price
$19.82 per share
Strike price for stock option grant
Option expiration
June 1, 2036
Expiration date of Cohen’s Evommune stock options
Rule 10b5-1 plan adoption date
March 3, 2026
Plan governing reported share sales
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to buy), annual meeting of stockholders
4 terms
Rule 10b5-1 trading plan regulatory
"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to buy) financial
"security_title: Stock Option (Right to buy)"
annual meeting of stockholders regulatory
"shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders"
FAQ
What insider transactions did Evommune (EVMN) director David E. Cohen report?
David E. Cohen reported selling 6,056 Evommune common shares and receiving a new stock option grant. The sales were open-market transactions, and the option grant gives him the right to buy 15,673 shares at a fixed exercise price.
What are the terms of David E. Cohen’s new Evommune (EVMN) stock option grant?
He was granted options on 15,673 Evommune shares with a $19.82 exercise price, expiring on June 1, 2036. The options vest at the earlier of one year from grant or the next annual meeting, subject to his continued service.
What does weighted average sale price mean in the Evommune (EVMN) Form 4?
The filing notes each sale price is a weighted average of multiple trades within a price range. For example, shares were sold between $20.00 and $20.99, with the reported number reflecting the average price across all individual executions in that range.